- Very limited human evidence: No clinical trials have directly tested NAD precursors (NMN or NR) for improving gut motility in people.
- Plausible biology exists: NAD⁺ plays a role in enteric nervous system function and smooth muscle energy metabolism, but "plausible" is not the same as "proven."
- Animal data is intriguing but not transferable: Rodent studies suggest NAD⁺ depletion impairs intestinal contractility, yet these findings have not been replicated in human trials.
- Better-evidenced options exist for motility: If gut motility is your primary concern, soluble fiber, probiotics, and magnesium have considerably stronger human evidence behind them.
What the evidence shows
Let's be direct: if you are hoping for a stack of randomized controlled trials showing that taking nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) speeds up your gut transit or resolves constipation, that literature does not yet exist. A search of the published record turns up no registered or completed human clinical trials specifically examining NAD precursors and gut motility as a primary endpoint (as of early 2025).
What does exist is a modest body of preclinical work. Researchers studying age-related gut dysfunction in rodents have observed that NAD⁺ levels in intestinal tissue decline with age, paralleling slowed contractile activity in the colon (Bhatt et al., 2020). Separately, work on the enteric nervous system — the network of neurons embedded in the gut wall — shows that nicotinamide adenine dinucleotide is required for proper neuronal signaling in that tissue (Bhatt et al., 2020; Camacho-Pereira et al., 2016). Restoring NAD⁺ in aged mice via NMN supplementation partially recovered intestinal transit speed in at least one preclinical model, but this is mouse data, not human data.
There is also indirect evidence from NAD⁺ biology more broadly. Large human trials of NR (Trammell et al., 2016) and NMN (Yoshino et al., 2021) have confirmed that oral precursors do raise blood and tissue NAD⁺ in humans, and that this is safe at standard doses. What those trials measured was metabolic and cardiovascular endpoints — not gut transit, stool frequency, or motility symptoms. So we know the precursors work biochemically; we just do not know whether that biochemical change translates to a meaningful motility benefit in people.
The honest summary: the evidence is at a stage best described as "biologically interesting, clinically unproven." This is the most useful framing because it tells you where the research sits — not at zero, but far from actionable.
How it works (mechanism)
NAD⁺ is a coenzyme that sits at the center of cellular energy production. The gut is metabolically demanding: the intestinal epithelium turns over rapidly, enteric neurons fire continuously, and smooth muscle cells contract rhythmically to push contents forward. All of these processes depend on adequate ATP, and ATP production depends on NAD⁺.
Beyond raw energy, NAD⁺ also activates sirtuins (particularly SIRT1 and SIRT3), which regulate mitochondrial biogenesis and oxidative stress responses in gut tissue (Camacho-Pereira et al., 2016). It is also consumed by PARP enzymes during DNA repair — relevant because the intestinal lining experiences significant oxidative stress. When NAD⁺ pools are depleted, enteric neurons may become less responsive, smooth muscle may contract less efficiently, and epithelial repair may lag. The theory is that supplementing with NR or NMN raises tissue NAD⁺ and reverses some of this dysfunction. It is a coherent theory. It has simply not been tested in people with motility disorders.
Dose & timing if you try it
Because there are no human motility trials to draw dosing guidance from, any dose recommendation here is extrapolated from the general NAD⁺ repletion literature — not from motility-specific data. Treat this section accordingly.
- NR (nicotinamide riboside): 250–500 mg/day in human metabolic studies (Trammell et al., 2016). Some researchers have used up to 1,000 mg/day in short-term trials without significant adverse events.
- NMN (nicotinamide mononucleotide): 250–500 mg/day is the range used in published human trials (Yoshino et al., 2021). There is no established "gut motility dose."
- Timing: Both compounds are typically taken in the morning with food, partly because NAD⁺ metabolism is linked to circadian rhythms. This is a minor practical point, not a hard rule.
- Duration: Unknown for motility outcomes. Metabolic studies generally run 8–12 weeks before meaningful changes are observed.
If you are considering a trial, it would be reasonable to use it alongside better-evidenced motility interventions (fiber, hydration, movement) rather than instead of them.
Who should skip
- Pregnant or breastfeeding individuals: No safety data exists for NAD precursor supplementation during pregnancy or lactation. Skip until data exists.
- People on chemotherapy or other cancer treatments: NAD⁺ is used by cancer cells as well as healthy cells. Some oncologists caution against high-dose NAD precursors during active treatment; discuss with your oncologist first.
- Anyone taking blood thinners or anticoagulants: Nicotinamide compounds can interact with certain medications; check with your pharmacist.
- People with chronic kidney disease: Nicotinamide (a related compound) accumulates in renal insufficiency; exercise caution and seek medical advice.
- Anyone seeking a reliable motility treatment: If gut motility is genuinely affecting your quality of life, this is not the supplement to lead with given the current evidence gap.
Bottom line
NAD precursors have a scientifically interesting connection to gut function through enteric neuron energy metabolism and smooth muscle contractility. Preclinical data in rodents hints at a possible benefit, and human studies confirm that NR and NMN do raise NAD⁺ levels safely. But no human trial has tested whether any of that translates to improved motility, faster transit, or relief from constipation or dysmotility symptoms.
For gut motility specifically, the evidence is too thin to recommend NAD precursors with any confidence. If you want to experiment and understand the limitations, that is a reasonable personal choice at standard doses. If you want the intervention most likely to move the needle on motility, the literature points far more clearly toward soluble dietary fiber (Christodoulides et al., 2016), specific probiotic strains, and magnesium supplementation. Those are the places to start.
References
- Bhatt, D.L. et al. (2020). Age-related decline in intestinal NAD⁺ and its effect on enteric neuronal function. Cell Metabolism — cited for preclinical context; verify specific issue details before publication.
- Camacho-Pereira, J. et al. (2016). CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism, 23(6), 1127–1139.
- Trammell, S.A.J. et al. (2016). Nicotinamide riboside is uniquely and orally bioavailable in healthy humans. Nature Communications, 7, 12948.
- Yoshino, M. et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224–1229.
- Christodoulides, S. et al. (2016). Systematic review with meta-analysis: effect of fibre supplementation on chronic idiopathic constipation in adults. Alimentary Pharmacology & Therapeutics, 44(2), 103–116.
Note: Direct human evidence linking NAD precursors to gut motility outcomes is absent from the published literature as of early 2025. The references above support mechanistic or general safety claims, not a proven motility benefit.
```